In the second positive phase 3 trial of lumateperone (Caplyta) for bipolar mania, participants saw improved manic symptoms vs placebo as early as day 3.
|Slideshows|March 15, 2018
A New Tool for Springtime Mania
Author(s)Chris Aiken, MD
An environmental approach to mania makes it possible to “slow down the sun” and modulate the destabilizing effects of spring sunlight. More in this report.
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Psychiatric Times
1
Cannabis Use Prevalent In Substance-Related Adolescent Emergency Care: Insights From Kevin Xu, MD
2
NDA Submission Complete: COMP360 Psilocybin for Treatment-Resistant Depression
3
Lumateperone Shows Significant and Rapid Improvement in Bipolar Mania
4
Schizo-Obsessed! Untangling the Overlap Between Obsessive Compulsive Disorder and Schizophrenia
5